Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
Remyelination therapy goes to trial for multiple sclerosis
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
Disease-modifying treatments for progressive multiple sclerosis.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease.
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
Pediatric multiple sclerosis.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Prospective memory, emotional valence, and multiple sclerosis.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
The potential role of epigenetic modifications in the heritability of multiple sclerosis.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Company restores access to multiple sclerosis drug after pressure from neurologists.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.

Pages